Carl Weissman

Carl Weissman serves as President and CEO of Accelerator, a joint investment vehicle backed by a syndicate of venture capital firms. Accelerator invests in and actively manages emerging biotechnology companies. Carl also serves as a Venture Partner at OVP Venture Partners and focuses on the digital biology sector. He serves on the Board of Directors for Allozyne, Accelerator and Fate, and is a Board Observer to CODA Genomics, NanoString, and Viral Logic Systems Technology (VLST). Carl was previously a Venture Partner at MPM Capital. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the board of the WBBA and is Vice President of the Board of Teens in Public Service.